Bellicum Pharmaceuticals Recommended for $16.9 Million Award from the Cancer Prevention and Research Institute of Texas
CPRIT funds would support comparative outcomes clinical trials of BPX-501 in AML patients
Assuming successful contract negotiations and execution, the CPRIT award would fund a portion of a three-year global clinical program comprising clinical trials for adult and pediatric patients with high- and intermediate-risk acute myeloid leukemia (AML). The proposed studies are designed to evaluate the benefit of BPX-501 and rimiducid in the context of in vivo and ex vivo T-cell depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
“We are proud to have been approved by CPRIT and its Oversight Committee
for this award to help accelerate the clinical development of BPX-501
and rimiducid in hematologic cancers,” said
About CPRIT
To date, CPRIT has awarded
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Forward-Looking Statement
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue," “designed,”
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
research and development activities relating to BPX-501, rimiducid,
CAR-T and TCR programs; the success of our contract negotiation with
CPRIT and our acceptance of the award; the effectiveness of BPX-501, its
possible range of application and potential curative effects and safety
in the treatment of diseases including as compared to other treatment
options and competitive therapies; the timing and success of our
clinical trials, including the rate and progress of enrollment in our
clinical trials, such as our planned AML trial; and, the timing of
regulatory filings for BPX-501 and for rimiducid. Various factors may
cause differences between Bellicum’s expectations and actual results as
discussed in greater detail under the heading “Risk Factors” in
Bellicum’s filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20161116006400/en/
Source:
Investors:
Bellicum Pharmaceuticals
Alan Musso,
832-384-1116
CFO
amusso@bellicum.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com